COMPANY
Ioncologi Inc.
iOncologi, Inc. is a clinical-stage biopharmaceutical company. From company website Source · Oct 12, 2026
NIH awards 2
- NIH award 4R42CA302331-02 FY2026: $1,006,593 awarded for that fiscal year; activity R42 (STTR); PI RODRIGUEZ, EDGARDO; recipient as written: IONCOLOGI INC, GAINESVILLE, FL. Overcoming Immune Checkpoint Blockade Resis source ↗
- NIH award 1R42CA302331-01 FY2025: $276,544 awarded for that fiscal year; activity R42 (STTR); PI RODRIGUEZ, EDGARDO; recipient as written: IONCOLOGI INC, GAINESVILLE, FL. Overcoming Immune Checkpoint Blockade Resista source ↗
Funding and NIH signals
- NIH award NIH awarded $1.01M (STTR Phase II 4R42CA302331-02, extension, notice Sep 17, 2026). NIH RePORTER 4R42CA302331-02 (Sep 17, 2026)
Evidence (1 event)
- Sep 17, 2026 · NIH RePORTER 4R42CA302331-02
Organization: IONCOLOGI INC; City/State: GAINESVILLE, FL; Project number: 4R42CA302331-02; Activity code: R42; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 1006593; Administering IC: National Cancer Institute; Project title: Overcoming Immune Checkpoint Blockade Resistance in Glioblastoma with a Novel Stem Cell Biotherapeutic; Organization type: Domestic For-Profits
- Sep 17, 2026 · NIH RePORTER 4R42CA302331-02